Arrowhead Pharmaceuticals

Phase A — Understand the business

Lens 1 · Company Overview

Arrowhead develops RNA interference (RNAi) therapeutics — short interfering RNA (siRNA) drugs that silence the expression of disease-associated genes by degrading their messenger RNA before the protein is ever made. The core IP is the proprietary TRiM™ (Targeted RNAi Molecule) platform, which conjugates the siRNA trigger to targeting ligands to deliver it into specific tissues. The platform's differentiating claim: TRiM "currently enables delivery of siRNA to seven cell types", i.e. it reaches beyond the liver — the tissue every GalNAc-conjugated competitor is confined to.

Business model — two engines:

1. Partner the big indications for non-dilutive capital. Arrowhead licenses programs it does not intend to commercialize itself to large pharma — "Sarepta Therapeutics, Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Glaxosmithkline... and Novartis Pharma AG" — collecting upfronts, milestones, and royalties. This is where ~all reported revenue comes from today.
2. Self-commercialize the rare/orphan indications where a small commercial footprint suffices. The first such product: REDEMPLO® (plozasiran), FDA-approved 2025-11-18 for Familial Chylomicronemia Syndrome (FCS) — Arrowhead's first commercial medicine.

Key economic terms. Revenue is recognized on collaboration accounting — upfronts and milestones land in discrete quarters, so the P&L is violently lumpy (FY24 revenue $3.6M → FY25 $829.4M). The embedded optionality is enormous: as of 2026-03-31 the company is "eligible to receive up to $15.2 billion in additional developmental, regulatory and sales milestones" across partnered programs, plus royalties. That $15.2B is a gross, fully-unrealized, probability-unweighted ceiling — not a forecast.

HQ: Pasadena, CA. Incorporated: Delaware. Listing: Nasdaq Global Select (ARWR). Fiscal year: ends Sept 30. Shares: 135,809,558 outstanding as of 2025-11-19; weighted basic 142.4M for the quarter ended 2026-03-31 (share count climbing via raises — see Lens 10/13).

Lens 2 · Supply Chain

For a drug developer the "supply chain" is the discovery → CDMO manufacturing → regulatory → channel path plus the partner web that monetizes it. Named stakeholders along Arrowhead's chain:

• Upstream / inputs: Oligonucleotide synthesis and conjugation chemistry are the physical inputs. Arrowhead runs internal discovery and process development (it built out owned R&D/lab capacity — see the $382.5M PP&E balance and the 144,000 sq ft San Diego lab lease running to 2038). siRNA manufacturing at commercial scale is typically outsourced to specialist CDMOs (oligo manufacturers); the filings do not name a single-source CDMO as a disclosed dependency ``.
• The company: Arrowhead Pharmaceuticals + subsidiaries — Arrowhead Australia, NZ, Ireland, and Visirna Therapeutics (the China JV / variable-interest entity; see below).
• Downstream / monetization partners (the real "customers"):
• Sarepta Therapeutics — global license/collaboration (signed 2024-11-25) over muscle/CNS/lung rare-disease programs (ARO-DUX4, ARO-DM1, ARO-MMP7, ARO-ATXN2, + preclinical HTT/ATXN1/ATXN3). Largest revenue contributor: Sarepta drove $271.2M of 1H-FY26 revenue.
• Amgen (+ Royalty Pharma) — olpasiran (Lp(a) / cardiovascular); Arrowhead remains eligible for "up to an additional $485.0 million" in olpasiran milestones.
• Novartis — ARO-SNCA (alpha-synuclein / Parkinson's & synucleinopathies); $200M upfront, up to $2B milestones, closed 2025-10-17.
• Sanofi — Greater China rights to REDEMPLO; markets plozasiran in China post-NMPA approval; $10.7M of 1H-FY26 revenue.
• GSK — GSK-HSD (ARO-HSD, liver disease) exclusive license (2021).
• Takeda — fazirsiran / ARO-AAT (alpha-1 antitrypsin liver disease) co-development.
• Madrigal Pharmaceuticals — licensed ARO-PNPLA3 (MASH/NASH).
• Capital "supplier": Sixth Street Lending Partners — a $500M senior secured term loan ($400M funded) is structurally part of the chain because it funds the burn between deal-recognition quarters.

Chokepoints / single-source dependencies: (1) Sarepta concentration — one partner = the dominant revenue line; Sarepta's own well-publicized 2025 troubles (gene-therapy safety/financial stress) are a transmission risk into Arrowhead's milestone stream. (2) Plozasiran is the single self-commercialized product — the entire owned-revenue story rests on one molecule across its indication ladder. (3) The TRiM delivery chemistry is the irreplaceable internal input — it is the moat and the concentration.

Lens 3 · Competitive Advantages (moats)

The moat is extrahepatic delivery. RNAi's commercial history is a liver story: GalNAc conjugation reliably delivers siRNA to hepatocytes, and that's where Alnylam, Ionis, and the now-Novo-owned Dicerna built their franchises. The hard problem — the one worth a moat — is delivering siRNA outside the liver (muscle, CNS, lung, kidney). Independent trade coverage frames Arrowhead bluntly: it "has the most clinically advanced multi-tissue RNAi platform that exists, and the extrahepatic categories are not competitive in the same way as the liver category". The CNS proof point is striking — ARO-MAPT (tau) achieved "blood-brain-barrier penetration and deep knockdown of target genes across the central nervous system... after subcutaneous injections" in preclinical work. Subcutaneous CNS silencing, if it holds in humans, is a category-defining capability.

Moat sources, ranked:

1. Process / platform IP (durable): TRiM chemistries across seven cell types — a multi-year, multi-program lead in the hardest part of the field. This is what large pharma is paying upfronts to rent rather than build.
2. Validation-by-partner (strong signal, not a moat itself): Novartis ($200M up, $2B milestones), Sarepta, Amgen, GSK, Takeda, Sanofi, Madrigal all licensing the platform is a repeated revealed-preference vote that the chemistry works and is hard to replicate in-house.
3. Switching costs / data moat (medium): Long-duration siRNA dosing (quarterly+) and accumulated trial datasets create stickiness once a program is partnered and advanced.
4. First-mover in specific targets (medium): plozasiran (APOC3), olpasiran (Lp(a)), ARO-SNCA (alpha-synuclein) stake clinically-advanced positions on genetically-validated targets.

Bargaining power. Over partners: moderate and rising — a contested platform with seven would-be licensees has leverage on deal terms (the escalating upfronts — $200M Novartis — show it). Over the FDA/payers: none, like any drug developer. Weak spot: on its own commercial product (REDEMPLO) Arrowhead is a first-time, sub-scale commercial operator competing for orphan-disease share — no demonstrated commercial moat yet.

Lens 4 · Segments

Arrowhead does not report multiple operating segments — it is effectively one segment (RNAi therapeutics R&D + emerging commercial). The meaningful disaggregation is revenue by collaboration partner and opex by function, both ``:

Revenue by partner — 1H FY26 (six months ended 2026-03-31) vs prior-year half:

The trend that matters: 1H-FY26 total revenue fell YoY ($336.7M vs $545.2M) only because the prior-year half captured the giant Sarepta upfront recognition — but the composition improved markedly. Novartis and Sanofi are brand-new revenue lines in FY26, evidence the partnering engine is diversifying away from single-partner Sarepta dependence.

Opex by function — annual:

R&D up 20.0% YoY and has nearly doubled over three years — the pipeline is maturing into expensive late-stage trials (Phase 3 SHASTA program, CAPITAN CV outcomes trial). G&A jumped 25% in FY25 as commercial infrastructure for the REDEMPLO launch was built. This is the cost of the commercial transition: spend accelerates ahead of owned product revenue.

---

Phase B — Measure performance

Lens 5 · Pipeline by phase (+clinical swap for Earnings Result)

The asset table is the company. Key programs (modality = siRNA via TRiM unless noted):

Clinical de-risking signals (all, 2026): plozasiran delivered triglyceride reductions of −73% (MUIR) to −86% (SHASTA-2) sustained through 15 months, "generally well-tolerated." Breakthrough Therapy designation in sHTG (Dec 2025) is a meaningful FDA-confidence tell. The deprioritization of zodasiran is positive discipline — concentrating cardiometabolic spend on the winning APOC3 asset rather than running two overlapping programs.

The lumpy P&L (context, ): Q2-FY26 (quarter ended 2026-03-31) revenue $73.7M, operating loss $(141.3)M, net loss attributable $(132.7)M, EPS $(0.93) on 142.4M weighted shares. 1H-FY26: revenue $336.7M, operating loss $(100.5)M, net loss attributable $(101.9)M. FY2025 full year: revenue $829.4M, operating income $98.3M (first-ever), net loss attributable just $(1.6)M / EPS $(0.01) — but that profitability was entirely Sarepta-deal recognition, not recurring. Read the run-rate, not the headline: ex-deal quarters burn ~$130–140M operating. R&D ~$173M/quarter.

Lens 6 · Earnings Calls (sentiment trend)

Management's narrative has shifted decisively from "clinical-stage developer" to "commercial-stage, pivotal-year" company. The FY2026 calls explicitly frame 2026 as a "pivotal" year. Recurring themes management now leads with: the REDEMPLO launch ramp (>400 prescriptions, "greater than 40% growth over... the last four weeks" ); the diversification of the partner base (Novartis, Sanofi, Madrigal added); and the sHTG sNDA as the gating event. What they emphasize less than two years ago: pure platform/preclinical storytelling — the conversation is now about converting the platform into revenue. Tone: confident on science and partnering, measured on the (large, expensive) cash needs — they openly flag that "significant additional capital will be needed". Note: transcripts/ is empty in the research layer (0 files), so this lens is ``-grounded — a gap worth backfilling.

Lens 7 · Catalyst calendar + mechanism comps (+clinical swap for Comps)

Catalyst calendar (what de-risks or kills value, and when):

Mechanism comps (by modality/target, not P/E — the right peer frame for a platform):

The strategic read: Alnylam owns the liver and the profitability; Arrowhead owns the harder, less-contested extrahepatic frontier but trails on commercial proof. Dicerna's acquisition by Novo is the precedent that platform RNAi gets bought — relevant to any takeout optionality.

Lens 8 · Stock-Price Catalysts (what moves ARWR)

Pattern from the last ~2 years: ARWR is a catalyst stock that reacts hardest to (1) major partnership deals and (2) FDA/clinical events.

• Up: Sarepta deal (2024) — transformational, re-rated the equity; first FDA approval (REDEMPLO, Nov 2025); Novartis deal — stock "rocketed ~11%" on the $200M upfront; ARO-PNPLA3 licensing to Madrigal — up ~5.5%; the share outperformed the S&P 500 by +270.71% over the trailing year.
• Down: dilutive financings (the Jan 2026 equity + convertible raise) and the Q2-FY26 swing to a $(132.7)M loss pressured sentiment; zodasiran deprioritization was read as a pipeline narrowing.

What the market actually prices: the partner-validation cadence and the next clinical/regulatory binary — not current earnings (there are none on a run-rate basis). This is an options-on-the-pipeline stock. That cuts both ways: it re-rates violently on good news and punishes dilution/clinical disappointment just as hard.

---

Phase C — Judge people & books

Lens 9 · Management

Christopher Anzalone, PhD — President, CEO & Director since Dec 1, 2007 (~18 years). This is a founder-archetype operator, not a hired-gun manager.

1. Track record: Took over a near-shell (Arrowhead Research), survived the 2008 crash that hit immediately after he arrived, pivoted the entire company onto RNAi, and built it into a platform that just landed its first FDA approval and a string of pharma partnerships. The trailing-year stock outperformed the S&P 500 by +270.71%. Survivor-builder with a multi-cycle thesis — a genuine "adversity odyssey".
2. Tenure & skin in the game: ~18 years; owns ~3.79M shares ≈ 4.0% of the company (~$313M) — "management incentives are well aligned with other shareholders". Material, founder-level alignment.
3. Capital allocation: The defining strategic choice — fund the burn with partner upfronts and milestones (non-dilutive) rather than pure equity — is shrewd and has scaled (Novartis $200M up / $2B milestones is best-in-class deal-making). Reinvestment is heavy and rising (R&D +20% to $607M FY25). The blemish: the 15% PIK Sixth Street facility is expensive capital, and the company still had to do a dilutive Jan-2026 equity + convertible raise — so the non-dilutive strategy is necessary but not sufficient.
4. Red flags: Routine, programmatic CEO share sales (multiple Form 4s, incl. Dec 2025). At ~4% retained ownership and 10b5-1-style cadence, these read as normal diversification, not a governance flag — he remains heavily exposed. No related-party or restatement issues surfaced.
5. Archetype implication: Founder-scientist who has earned long-leash credibility on the science and the partnering model; the open question is whether a development-first culture can execute a commercial launch — a genuinely different muscle.

Lens 10 · Forensic Red Flags

Forensic lens, every figure unless noted.

• Revenue recognition is the #1 watch-item. Revenue is collaboration accounting — upfronts/milestones recognized in lumps (FY24 $3.6M → FY25 $829.4M → 1H-FY26 $336.7M). FY2025's operating profit ($98.3M) and near-breakeven net result are non-recurring deal artifacts, not earning power. Anyone valuing ARWR off a trailing P/E is being misled by the accounting. Deferred revenue is small ($2.4M at 9/30/25), so there's little "stored" revenue cushioning future quarters.
• Receivables outrunning revenue: accounts receivable swung from $0 to $6.8M (9/30/25) and to $15.7M (3/31/26), and the FY25 cash-flow statement shows a $(57.0)M working-capital drag from receivables — a function of milestone timing, worth monitoring but explained.
• Debt + royalty-monetization layering (real risk): Liability related to sale of future royalties $367.4M; credit facility $254.9M total (current+LT) at 9/30/25. Non-cash interest is heavy — FY25 interest expense $89.4M, including $63.3M non-cash interest on the credit facility and $26.0M non-cash on the royalty liability. These are GAAP charges that flatter cash but accrete the obligations; the Sixth Street facility carries a 15% rate, PIK, no amortization, principal due Aug 2031 — that interest compounds against the equity.
• SBC: $63.4M FY25 (down from $74.0M FY24) — large in absolute terms (~8% of opex) but trending down; standard biotech dilution vector.
• Noncontrolling interest / VIE (Visirna, China): A consolidated VIE holds material restricted cash ($137.8M at 9/30/25, $41.0M at 3/31/26) and generated a $31.7M NCI income swing in FY25. The reported "net income including NCI" of $30.1M vs net loss attributable to Arrowhead of $(1.6)M is entirely the VIE — read the attributable line. A China-JV VIE adds structural and geopolitical complexity to the consolidation.
• Going concern: No going-concern qualification. Management states "sufficient liquidity to fund its operations through at least the next twelve months" from each filing date. With ~$1.78B liquidity at 3/31/26 (see Lens 11), near-term solvency is not the issue; recurring dilution to refill is.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: None. Verified via SEC EDGAR EFTS (LR + AAER) for "Arrowhead Pharmaceuticals," period 2021-06-20 → 2026-06-20 — total_sec_findings: 0.
• 10-K Item 3 (Legal Proceedings): Incorporated by reference to Note 7 (Commitments & Contingencies) — no material litigation broken out as a standalone disclosure in Item 3. Note: one secondary source referenced "significant intellectual property litigation" as a risk theme; IP disputes are routine in the RNAi/oligo space (the field has a dense, contested patent estate) — flagged as a watch-item, not a confirmed material adverse finding.
• Non-SEC enforcement (FTC/DOJ/FDA/etc.): No material enforcement actions surfaced in web search.
• Conclusion: No material regulatory or accounting-enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-20. The genuine accounting risk is interpretive (deal-revenue lumpiness + debt/royalty layering), not enforcement.

---

Phase D — Project & stress-test

Lens 11 · rNPV + runway-to-catalyst (+clinical swap for Forward Projection)

For a company whose GAAP EPS is a deal-recognition artifact, an EPS model is the wrong tool. The two questions that matter: (a) does cash reach the value-inflection catalysts, and (b) what is the lead asset worth risk-adjusted?

Runway to catalyst — the decisive analysis:

• Liquidity at 2026-03-31: $188.5M cash & equivalents + $1,595.6M available-for-sale securities ≈ $1.78B (the AFS book ballooned from $692.8M at 9/30/25 — funded by the Novartis $200M upfront, Sanofi, milestones, and the Jan-2026 equity+convert raise).
• Cash burn ex-deals: operating loss ~$130–140M/quarter; net cash used in operations in non-deal periods runs at a similar clip. Call it ~$500–560M/year of structural burn.
• **Runway: comfortably >3 years of structural burn covered by the AFS book alone ** — and that ignores all incoming milestones and the $15.2B partnered milestone ceiling. Management's "≥12 months" statement is conservative; the real runway clears the YE2026 sNDA, the mid-2026 Phase 3 readouts, and the EU launch with wide margin. Cash is not the near-term risk. The risk is the price of refilling it (15% PIK debt + dilution) over a multi-year horizon.

rNPV of plozasiran (lead asset, illustrative — every input ):

• FCS (approved): small orphan market, modest peak sales ``; PoS ≈ 1.0 (approved).
• sHTG (the prize): a far larger cardiometabolic population; Breakthrough Therapy + strong Phase 3-class efficacy (−73% to −86% TG) → assign a high (~70–80%) PoS to approval given data already in hand and BTD . Peak sales potential in the **multi-$B** range if the CV-outcomes story (CAPITAN) eventually broadens the label .
• Honest limit: I could not source a published consensus rNPV or peak-sales number for plozasiran sHTG — so the dollar figures above are labeled `` and the precise magnitude is n/a. The direction is unambiguous: sHTG is the value driver; FCS alone does not justify the ~$11.5B market cap.

No forecast.ts forecast logged (per --watchlist rules — no create step). The scoreable binary to track when promoted: "Plozasiran sHTG sNDA accepted by FDA by 2027-06-30."

Lens 12 · Bull vs Bear

Bull case. Arrowhead owns the only clinically-advanced multi-tissue RNAi platform — the part of the field large pharma can't replicate and is paying escalating upfronts to rent (Novartis $200M; ~$15.2B of partnered milestones outstanding). It has crossed the highest-risk chasm — first FDA approval (REDEMPLO) — proving the platform makes real drugs. The near-term re-rate is plozasiran in sHTG: Breakthrough Therapy, Phase 3-class efficacy already shown, sNDA by YE2026, opening a market orders of magnitude bigger than FCS. Behind it sits a deep, partnered, mostly-funded pipeline across cardiometabolic, CNS (Novartis/Parkinson's), muscle (Sarepta), and lung. ~$1.78B liquidity clears every 2026 catalyst. Dicerna's sale to Novo is the precedent that platform RNAi gets acquired — embedded takeout optionality. Founder-CEO with 18 years and 4% ownership. If plozasiran sHTG lands and one CNS/Parkinson's program advances, the platform is worth multiples of today's $11.5B.

Bear case (permanent-impairment risks).

1. Capital structure grinds the equity. The Sixth Street facility is 15% PIK debt with no amortization to Aug 2031 — interest compounds relentlessly — and the company still had to dilute (Jan-2026 equity + $700M then $625M converts; $1B shelf; convertible-debt covenant cap of $700M already hit). The non-dilutive partnering model is necessary but hasn't ended dilution. Every year to sustained product profitability is a year of value leaking to debt-holders and new shares.
2. Commercial execution is unproven. REDEMPLO is one orphan launch run by a first-time commercial org. >400 early scripts is encouraging but tiny; if Arrowhead can't actually sell drugs at scale, it's permanently a royalty/partnering shop valued well below an integrated biopharma.
3. Single-asset / single-partner concentration. Owned revenue = plozasiran; largest partner revenue = Sarepta (whose own 2025 stress is a live transmission risk). A plozasiran sHTG clinical/regulatory disappointment, or a Sarepta blow-up, removes the two largest value pillars at once.

Pre-mortem (it's late 2027, the thesis broke): the sHTG Phase 3 readouts disappointed or the sNDA stalled at FDA; REDEMPLO's FCS launch underwhelmed on payer coverage; meanwhile the 15% PIK accrued and another dilutive raise was forced into a falling stock — the equity compounded down. The platform was still scientifically real, but the equity was the casualty of leverage + a missed binary.

Are multiples too high? Trailing multiples are meaningless (no recurring earnings; P/E negative on a run-rate basis). At ~$11.5B vs ~$622M lumpy TTM revenue (~18x P/S on deal revenue), the stock is priced as a validated platform with sHTG optionality already partly in the price — not cheap, not euphoric. The valuation is a bet on the YE2026 sNDA and the milestone ladder converting.

Contrarian view — what the market is refusing to see: the consensus is split and confused (price targets range $17 to $100; "Strong Buy" rating yet one tracked "average target" of $63.7 sits below the ~$82 price ). The market is treating ARWR as a binary-event lottery and under-weighting the portfolio nature of the platform: with seven blue-chip partners and $15.2B of milestones spread across many shots on goal, the probability that essentially all of them fail is low — yet the equity trades closer to single-asset risk. The asymmetry, if the balance sheet is survived, favors the patient owner.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• Where revenue is concentrated: owned revenue is one molecule (plozasiran); reported revenue leans on one partner (Sarepta). Both are single points of failure, and Sarepta is itself a distressed counterparty in 2025 — a milestone slip or renegotiation there directly dents Arrowhead.
• Why the moat may be weaker than bulls think: "extrahepatic delivery leadership" is largely a preclinical/early-clinical claim outside the liver. The CNS subQ knockdown is preclinical; ARO-RAGE/ARO-MAPT are Phase 1/2a or IND-stage. If extrahepatic delivery proves harder in humans than in mice (the graveyard of delivery science), the differentiating moat thins to "another GalNAc/liver player" — where Alnylam already dominates and is profitable.
• Most dangerous competitor bulls underestimate: Alnylam — $4.3B revenue, profitable, layered patents, and actively pushing into extrahepatic itself; a well-capitalized incumbent that can out-spend and out-litigate. Plus Novo (via Dicerna) now has RNAi inside a pharma balance sheet.
• Worst capital-allocation marks: taking 15% PIK debt is a tell that cheaper capital wasn't available on acceptable terms; layering royalty monetizations ($367M liability) mortgages future product economics; and the repeated equity raises into the story show the funding treadmill never stopped.
• Assumptions that must hold for ~$82: (1) sHTG sNDA succeeds and approves; (2) REDEMPLO ramps into a real commercial franchise; (3) the partner milestones actually convert; (4) no forced down-round dilution. If growth/approval disappoints by 20–30%, the multiple has nothing to stand on (no earnings floor) and the equity can halve — exactly the kind of biotech that round-trips a 270% run.
• Single scenario that permanently impairs: plozasiran sHTG Phase 3 misses or the FDA rejects the sNDA → the central value driver evaporates, the platform reverts to "promising but unproven extrahepatically," and the 15% PIK keeps compounding against a smaller equity. Plausibility: moderate-low (data already strong, BTD granted) but non-trivial — and it's the whole ballgame.

Lens 14 · Management Questions (ordered by information value)

1. Plozasiran sHTG: what is the gating risk to filing the sNDA by year-end 2026 — purely data timing, or any open CMC/label question with FDA?
2. On the Sixth Street 15% PIK facility — what is the refinancing or repayment plan before Aug 2031, and at what equity cost do you model it accreting?
3. Given the convertible-debt covenant cap ($700M, already reached) and the $1B shelf, how many more dilutive raises does the plan to sustained product profitability require, and at what assumed share price?
4. What is REDEMPLO's payer coverage and net-price trajectory in FCS so far, and what does it imply for an sHTG launch where the population is far larger and payer scrutiny higher?
5. How exposed is your milestone stream to Sarepta's financial/operational stress — are any near-term Sarepta milestones at risk of slip or renegotiation?
6. Of the $15.2B partnered milestone ceiling, what fraction is development-stage (low-probability) vs regulatory/sales-stage, and what's a realistic risk-adjusted NPV?
7. Extrahepatic delivery in humans: what human (not preclinical) data do you have that subQ CNS/lung knockdown translates, and when do we see the first clinical proof for ARO-MAPT / ARO-RAGE?
8. What is the strategic logic of self-commercializing FCS/sHTG rather than partnering them — and at what scale of sHTG opportunity would you reconsider and partner?
9. On the Visirna China VIE: what is the long-term plan (consolidate, spin, IPO), and how do you frame its geopolitical and consolidation risk to U.S. holders?
10. CAPITAN CV-outcomes trial: what is the realistic readout timeline and the cost commitment, and how do you fund a multi-year outcomes study through the burn?
11. Zodasiran deprioritization — is a partner-out still expected, and does it signal anything about ANGPTL3 as a target vs APOC3?
12. What does the commercial org look like headcount/cost-wise, and how do you avoid over-building SG&A ahead of approvals?
13. Capital-allocation priority if a large milestone lands: de-lever the 15% PIK, fund CAPITAN, or expand the owned commercial footprint?
14. Which two pipeline assets beyond plozasiran do you believe the market is not pricing at all today?
15. What would have to be true for you to consider a sale of the company — and does the Dicerna/Novo precedent inform how you think about it?

---